Quick Answer
BioNexus Gene Lab Corp reported Cash and Equivalents of $2.12 million for fiscal year 2021.
BioNexus Gene Lab Corp Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2021 | $2.12M | -23.8% |
| 2020 | $2.79M | +224.5% |
| 2019 | $859.1K | -31.8% |
| 2018 | $1.26M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| March 31, 2022 | $1.84M | -25.5% | -13.2% |
| December 31, 2021 | $2.12M | -23.8% | +24.9% |
| September 30, 2021 | $1.70M | -22.4% | +14.7% |
| June 30, 2021 | $1.48M | +15.2% | -40.1% |
| March 31, 2021 | $2.47M | +77.2% | -11.2% |
| December 31, 2020 | $2.79M | +224.5% | +27.3% |
| September 30, 2020 | $2.19M | +124.1% | +70.2% |
| June 30, 2020 | $1.29M | +12.9% | -7.8% |
- BioNexus Gene Lab Corp showed a decrease of -23.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2021 period, BioNexus Gene Lab Corp’s cash and equivalents has grown by 68.5% (from $1.26 million to $2.12 million).
- The most recent figure is from BioNexus Gene Lab Corp’s fiscal year 2021 report (Form 10-K), filed with the SEC on April 6, 2022.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: